Inpatient Management of Hepatic Encephalopathy : Hepatology | June 2026

Introduction:

Hepatic encephalopathy (HE) is a major cause of hospitalization in patients with advanced liver disease and is associated with significant morbidity, mortality, and healthcare utilization. The management of HE extends beyond ammonia reduction and requires a comprehensive strategy addressing precipitating factors, nutritional support, organ dysfunction, and disease-specific complications. Importantly, the approach varies according to the underlying clinical context, including decompensated cirrhosis, acute-on-chronic liver failure (ACLF), and acute liver failure (ALF).

Problem Statement:

Patients admitted with overt HE often present with multiple concurrent complications that contribute to neurological deterioration. Failure to identify reversible precipitants or recognize syndrome-specific management requirements can adversely affect outcomes. In particular, HE associated with ACLF and ALF presents unique challenges due to multiorgan failure, cerebral edema, and the potential need for emergency liver transplantation.

Summary:

This review provides a comprehensive overview of the inpatient management of HE across different clinical scenarios. In patients with decompensated cirrhosis, management begins with exclusion of alternative causes of altered mental status, followed by prompt identification and correction of precipitating factors such as infection, gastrointestinal bleeding, electrolyte disturbances, constipation, and renal dysfunction. Nutritional optimization and pharmacological therapies aimed at reducing ammonia production remain central components of care. In ACLF, HE often occurs in conjunction with other organ failures and frequently necessitates intensive care management. Treatment focuses on aggressive management of precipitating events, organ support, and consideration of emergency liver transplantation in carefully selected candidates. The review highlights that ALF represents a distinct clinical entity in which rapidly rising ammonia levels may lead to cerebral edema and intracranial hypertension. Consequently, management includes specialized neuroprotective strategies, close neurological monitoring, osmotic therapy for intracranial pressure control, and extracorporeal ammonia-lowering approaches such as continuous renal replacement therapy and therapeutic plasma exchange. Across all etiologies, patients with grade 3–4 HE require intensive care monitoring because of the high risk of airway compromise and aspiration. The review reinforces the importance of individualized, syndrome-specific management pathways to optimize outcomes in hospitalized patients with HE.